Altogether, our data showed that AR-C and SYRO by inhibiting MCT1 and MCT4 respectively, inhibit lactate metabolism and leukemic cell proliferation by inducing two different cell-death related pathways in AML cells i.e., necrosis for AR-C; autophagy for SYRO, a dual inhibitor of MCT1 and 4 but with a major affinity for MCT4 involved in lactate export in leukemic cells overexpressing this transporter. Here, ARC is linked to acute myeloid leukemia.